ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2014
Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Progranulin serum levels in human kidney transplant recipients: A longitudinal study.PloS one · 2018Trial
- Fatty acid metabolism: opportunities and challenges of traditional Chinese medicine in the treatment of renal fibrosis.Chinese medicine · 2026Review
- From fat to filter: the effect of adipose tissue-derived signals on kidney function.Nature reviews. Nephrology · 2025Review
- Article
- Adipose tissue metabolic changes in chronic kidney disease.Immunometabolism (Cobham, Surrey) · 2023Review
- New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease.Biomedicines · 2022Review
- Globular adiponectin inhibits osteoblastic differentiation of vascular smooth muscle cells through the PI3K/AKT and Wnt/β-catenin pathway.Journal of molecular histology · 2021Article
- Comorbidity burden may explain adiponectin's paradox as a marker of increased mortality risk in hemodialysis patients.Scientific reports · 2021Article
- Macrophage and adipocyte interaction as a source of inflammation in kidney disease.Scientific reports · 2021Observational
- Adiponectin in Chronic Kidney Disease.International journal of molecular sciences · 2020Review
- Adiponectin in renal fibrosis.Aging · 2020Review
- Dual inhibition of cannabinoid CBBritish journal of pharmacology · 2020Article
- Adiponectin for the treatment of diabetic nephropathy.The Korean journal of internal medicine · 2019Review
- The association of adiponectin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease.PloS one · 2019Article
- The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index.Oxidative medicine and cellular longevity · 2019Article
- Paradoxical positive association of serum adiponectin with all-cause mortality based on body composition in Japanese haemodialysis patients.Scientific reports · 2018Article
- Uric acid upregulates the adiponectin‑adiponectin receptor 1 pathway in renal proximal tubule epithelial cells.Molecular medicine reports · 2018Article
- Long-term study of the association of adipokines and glucose variability with diabetic complications.The Korean journal of internal medicine · 2018Article
- Immunologic and endocrine functions of adipose tissue: implications for kidney disease.Nature reviews. Nephrology · 2018Review
- Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review.Archives of endocrinology and metabolism · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAdiponectin plasma levels in chronic kidney disease (CKD) are two to three times higher than in individuals with normal kidney function. Despite adiponectin's anti-diabetic, anti-inflammatory and anti-atherogenic properties, patients with CKD have insulin resistance, systemic inflammation and accelerated atherogenesis. Hence, although adiponectin production is increased by adipose tissue in end-stage renal disease (ESRD), it is unclear if its effects on metabolism remain intact.
methodsTo determine if there is adiponectin resistance in ESRD, we measured tissue levels of adiponectin receptor-1 (AdipoR1) and adiponectin downstream effectors in ESRD patients compared with normal kidney function controls. Blood and tissue samples were obtained from participants at the time of kidney transplantation or kidney donation. A follow-up blood sample was obtained 3-6 months after transplantation.
resultsAdipoR1 was higher in muscle and peripheral blood mononuclear cells collected from ESRD patients. There was also a nonsignificant increase in AdipoR1 in visceral fat of ESRD compared with controls. Compared with controls, phosphorylation of the adiponectin downstream effector adenosine monophosphate-activated protein kinase (AMPK) was higher in ESRD while acetyl-CoA carboxylase phosphorylation (ACC-P) and carnitine palmitoyl transferase-1 (CPT-1) levels were lower. In vitro, exposure of C2C12 cells to uremic serum resulted in upregulation of AdipoR1 and increased phosphorylation of AMPK but decreased ACC-P and CPT-1 expression.
conclusionBoth our in vivo and in vitro observations indicate that uremia results in upregulation of AdipoR1 but adiponectin resistance at the post-receptor level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.